John Roddy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
John Roddy has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Paul Anthony Bergl
Division of Pulmonary, Critical Care, and Sleep Medicine at the Medical College of Wisconsin, Milwaukee, WI
2 shared publications - Daniel Msn Wells
Immunai, Inc., New York, USA
1 shared publication Jesus Rodriguez
1 shared publication- Jesús Hernández Hernández
Sección de Neumología, Complejo Asistencial de Ávila, Ávila, España
1 shared publication - Jonathan S. Kurman
Medical College of Wisconsin Division of Pulmonary & Critical Care Milwaukee, WI
1 shared publication - Karen-Sue Carlson
Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
1 shared publication
Latest Publications
- Open Access
- 11 May 2022
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 4 (5) , e0702
Tocilizumab Versus Baricitinib in Patients Hospitalized With COVID-19 Pneumonia and Hypoxemia: A Multicenter Retrospective Cohort Study
OBJECTIVES: In patients hospitalized with COVID-19 pneumonia, both tocilizumab and baricitinib have been shown to have clinical benefit compared with placebo. To date, there are few data comparing the two treatments, and their relative benefits and harms are unknown. This study aims to evaluate the effectiveness of tocilizumab versus baricitinib in patients hospitalized with COVID-19 pneumonia and hypoxemia. DESIGN: Retrospective cohort study. SETTING: Seven inpatient acute-care hospitals in Wisconsin. PARTICIPANTS: Patients hospitalized with COVID-19, hypoxemia, and Pao 2-to-Fio 2 ratio less than or equal to 300 mm Hg, who received either tocilizumab or baricitinib. INTERVENTIONS: Electronic chart review. MEASUREMENTS AND MAIN RESULTS: Patients were divided into tocilizumab and baricitinib cohorts based on actual medication received. The primary outcome was hospital discharge alive and free from mechanical ventilation within 60 days, assessed by logistic regression. Three hundred eighty-two patients were included: 194 in the tocilizumab cohort and 188 in the baricitinib cohort. Most baseline characteristics in the two cohorts were similar. All patients received dexamethasone. Two patients were lost to follow-up. In the remaining 380 patients, probability of successful discharge in the two cohorts was quantitatively similar in unadjusted, multivariate-adjusted, and propensity score-matched analyses. Hospital length of stay, rates of thromboembolic events, and rates of hospital-acquired infections were all similar in the two cohorts. CONCLUSIONS: In patients hospitalized with COVID-19 pneumonia and hypoxemia who receive dexamethasone, treatment with tocilizumab or baricitinib appears to result in similar outcomes.
- 11 May 2022
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 4 (5) , e0702
Open AccessTocilizumab Versus Baricitinib in Patients Hospitalized With COVID-19 Pneumonia and Hypoxemia: A Multicenter Retrospective Cohort Study
OBJECTIVES: In patients hospitalized with COVID-19 pneumonia, both tocilizumab and baricitinib have been shown to have clinical benefit compared with placebo. To date, there are few data comparing the two treatments, and their relative benefits and harms are unknown. This study aims to evaluate the effectiveness of tocilizumab versus baricitinib in patients hospitalized with COVID-19 pneumonia and hypoxemia. DESIGN: Retrospective cohort study. SETTING: Seven inpatient acute-care hospitals in Wisconsin. PARTICIPANTS: Patients hospitalized with COVID-19, hypoxemia, and Pao 2-to-Fio 2 ratio less than or equal to 300 mm Hg, who received either tocilizumab or baricitinib. INTERVENTIONS: Electronic chart review. MEASUREMENTS AND MAIN RESULTS: Patients were divided into tocilizumab and baricitinib cohorts based on actual medication received. The primary outcome was hospital discharge alive and free from mechanical ventilation within 60 days, assessed by logistic regression. Three hundred eighty-two patients were included: 194 in the tocilizumab cohort and 188 in the baricitinib cohort. Most baseline characteristics in the two cohorts were similar. All patients received dexamethasone. Two patients were lost to follow-up. In the remaining 380 patients, probability of successful discharge in the two cohorts was quantitatively similar in unadjusted, multivariate-adjusted, and propensity score-matched analyses. Hospital length of stay, rates of thromboembolic events, and rates of hospital-acquired infections were all similar in the two cohorts. CONCLUSIONS: In patients hospitalized with COVID-19 pneumonia and hypoxemia who receive dexamethasone, treatment with tocilizumab or baricitinib appears to result in similar outcomes.
- Open Access
- 7 June 2021
- Published by Wiley in British Journal of Haematology
- Vol. 194 (6) , 1083-1085
Revisiting biochemistry: severe euglycemic ketoacidosis in the setting of IDH‐inhibitor therapy for AML
- 7 June 2021
- Published by Wiley in British Journal of Haematology
- Vol. 194 (6) , 1083-1085
Open AccessRevisiting biochemistry: severe euglycemic ketoacidosis in the setting of IDH‐inhibitor therapy for AML
- Open Access
- 16 March 2021
- Published by BMJ in BMJ Case Reports
- Vol. 14 (3) , e240385
Prone positioning for severe ARDS in a postpartum COVID-19 patient following caesarean section
A 31-year-old pregnant woman presented with symptomatic COVID-19, which was complicated by progressive hypoxaemia requiring intensive care and emergent delivery by caesarean section. Afterward, she was successfully supported with mechanical ventilation and prone positioning and ultimately recovered. We review literature regarding complications of COVID-19 affecting pregnancy and evidence-based treatment strategies.
- 16 March 2021
- Published by BMJ in BMJ Case Reports
- Vol. 14 (3) , e240385
Open AccessProne positioning for severe ARDS in a postpartum COVID-19 patient following caesarean section
A 31-year-old pregnant woman presented with symptomatic COVID-19, which was complicated by progressive hypoxaemia requiring intensive care and emergent delivery by caesarean section. Afterward, she was successfully supported with mechanical ventilation and prone positioning and ultimately recovered. We review literature regarding complications of COVID-19 affecting pregnancy and evidence-based treatment strategies.
- Open Access
METABOLITE MISHAP: A NOVEL CAUSE OF KETOACIDOSIS